Moving to NASDAQ once FDA designation is grantedWith a FDA designation (Breakthrough Therapy or Accelerated Approval), we will move to NASDAQ, just like all the other biotechs. This is where our market valuation will grow to fair valuation.
We will be able to raise capital so we can advance GBM, NSCLC and vaccine much faster and to prepare for marketing NMIBC, before a jv. This will be seen as something very positive for our market valuation, in order to have more money in the kitty, ahead of big pharmas negociations for a jv on NMIBC rights. If we want TLT to be independent in these negociations, that's what will have to happen. Expect a road show after such FDA desingation. The phone will start ringing with serious US brokage firms that are capable of bringing us much higher.
Raising money will be extremely positive at this stage as FDA designation will attract this time real hungry investors that will want to move us much higher in valuation. Oncology innovations command 1B$US+ in market valuation, when you are a contender for the next SOC.